Global Pharmacovigilance and Risk Management Strategies Conference

Menu Back to Global-Pharmacovigilance-and-Risk-Management-Strategies-Conference

Overview

February 6-8, 2023

DIA's Global Pharmacovigilance and Risk Management Strategies Conference was developed by recognized experts from the biopharmaceutical industry and global regulatory agencies. This conference provides the background, context, and opportunities to discuss current challenges alongside fresh problem-solving strategies that matter most to professionals working in the field.

While we develop our 2023 Agenda, please take a look at the 2022 final agenda.

Program Committee

Jeremy Jokinen, PhD, MS • Vice President and Head, Global Risk Management & International Patient Safety
Bristol-Myers Squibb Company, United States
Annette S. Williams, MBA, RPh • Vice President, Pharmacovigilance
IQVIA, United States
James Buchanan, PharmD • President
Covilance LLC, United States
Barbara Hendrickson, MD • Immunology Therapeutic Area Head, Pharmacovigilance and Patient Safety
AbbVie, Inc., United States
Mamiko Kasho • Executive Director, Global PV Management Dept., Global Safety HQs
Eisai Co., Ltd., Japan
Susan Kindig, JD, MD • Executive Director, Medical & Drug Safety
Halozyme, United States
Jamie Ridley Klucken, PharmD, MBA, RPh • Safety Evaluator, Division of Pharmacovigilance, OSE, CDER
FDA, United States
Mengchun Li, MD, MPA • Director, Phamacovigilance
Global Alliance For TB Drug Development, United States
Sarah Vaughan • Head of Vigilance Development
Medicines and Healthcare products Regulatory Agency (MHRA), United Kingdom
Jo Wyeth, PharmD • Associate Director for Postmarket Assessments, OMEPRM, OSE, CDER
FDA, United States